Trade

with

Hyperion Therapeutics Inc
(NASDAQ: HPTX)
AdChoices
22.76
+0.59
+2.66%
After Hours :
22.76
0.00
0.00%

Open

22.64

Previous Close

22.17

Volume (Avg)

248.78k (138.64k)

Day's Range

22.28-23.17

52Wk Range

18.97-32.98

Market Cap.

468.81M

Dividend Rate ( Yield )

-

Beta

0.89

Shares Outstanding

20.60M

P/E Ratio (EPS)

25.38 (0.90)

AdChoices
Fundamentals
  • Key statistics
  • Growth
  • Profitability
  • Financial health
  • Price ratios
  • Trading statistics
Industry Biotechnology
Highlights
Analyst Recommendation: Buy
    • Revenue

    • 42.20M

    • Net Income

    • 16.63M

    • Market Cap.

    • 468.81M

    • Enterprise Value

    • -

    • Net Profit Margin %

    • 21.30

    • PEG (Price/Earnings Growth) Ratio

    • -

    • Beta

    • 0.89

    • Forward P/E

    • 142.86

    • Price/Sales

    • 5.40

    • Price/Book Value

    • 3.11

    • Price/Cash flow

    • 14.27

      • EBITDA

      • 21.47M

      • Return on Capital %

      • 8.86

      • Return on Equity %

      • 14.47

      • Return on Assets %

      • 8.86

      • Book Value/Share

      • 7.32

      • Shares Outstanding

      • 20.60M

      • Last Split Factor (Date)

      • -

      • Last Dividend (Ex-Date)

      • -

      • Dividend Declaration Date

      • -

      Analyst Recommendation
      10/17/2014
      Buy
        • 1 Year Price Target

        • 38.00

        • Credit Rating

        • -

        • Analysts

        • 1

        • EPS Estimate

        • 1.85

        • Cashflow Estimate

        • -

        Morningstar Consensus estimate data
        • Growth Rate (%)

        • Company

        • Industry

          • Sales (Revenue)

            Q/Q (last year)

          • 407.80

          • 40.73

          • Net Income

            YTD/YTD (last year)

          • -

          • 17.04

          • Net Income

            Q/Q (last year)

          • -30.10

          • 98.90

          • Sales (Revenue)

            5-Year Annual Average

          • -

          • 63.43

          • Net Income

            5-Year Annual Average

          • -

          • 10.65

          • Dividends

            5-Year Annual Average

          • -

          • 15.81

          • Profit Margins (%)

          • Company

          • Industry

            • Gross Margin

            • 86.05

            • 82.75

            • Pre-Tax Margin

            • 19.11

            • 39.38

            • Net Profit Margin

            • 21.30

            • 31.33

            • Average Gross Margin

              5-Year Annual Average

            • -

            • 82.99

            • Average Pre-Tax Margin

              5-Year Annual Average

            • -

            • 33.42

            • Average Net Profit Margin

              5-Year Annual Average

            • -

            • 199.05B

            • Financial Ratios

            • Company

            • Industry

              • Debt/Equity Ratio

              • 0.00

              • 0.76

              • Current Ratio

              • 3.38

              • 2.92

              • Quick Ratio

              • 3.29

              • 2.35

              • Interest Coverage

              • 14.20

              • 38.02

              • Leverage Ratio

              • 2.00

              • 2.21

              • Book Value/Share

              • 7.32

              • 4.76

              • Price Ratios

              • Company

              • Industry

                • Current P/E Ratio

                • 26.04

                • 188.68

                • P/E Ratio 5-Year High

                • 36.76

                • 634.30

                • P/E Ratio 5-Year Low

                • 11.09

                • 124.82

                • Price/Sales Ratio

                • 5.55

                • 8.72

                • Price/Book Value

                • 3.19

                • 7.95

                • Price/Cash Flow Ratio

                • 14.27

                • 45.45

                • Key Metrics

                • Company

                • Industry

                  • Return on Equity %

                    (5-Year Average)

                  • 14.47

                    (-)

                  • 37.63

                    (27.20)

                  • Return on Assets %

                    (5-Year Average)

                  • 8.86

                    (-)

                  • 17.22

                    (13.81)

                  • Return on Capital %

                    (5-Year Average)

                  • 14.45

                    (-)

                  • 21.78

                    (17.31)

                  • Income/Employee

                  • 357.69k

                  • 117.08k

                  • Inventory Turnover

                  • 3.20

                  • 1.48

                  • Asset Turnover

                  • 0.42

                  • 0.55

                  Current Historical
                  Financials
                  • Income Statement
                  • Balance Sheet
                  • Cash Flow
                  Operating Income
                  -13.42M
                  Operating Margin
                  -31.79
                  Total Equity
                  -
                  Retained Earnings
                  -
                  Free Cashflow
                  -
                  Price/Cashflow
                  14.27
                  Ownership

                  Institutional Ownership

                  -

                  Top 10 Institutions

                  120.91%

                  Mutual Fund Ownership

                  33.65%

                  Float

                  47.93%

                  5% / Insider Ownership

                  0.94%

                  Corporate insiders or major stockholders reporting trading activity in the stock.

                  Top Mutual Fund Owners

                  Top Institutional Owners

                  Mutual Fund Name

                  Institution Name

                  • Mutual Fund Name

                  • Shares Held

                  • % Change

                  • % Outstanding

                  • Fidelity® Select Biotechnology Portfolio

                  •  

                    1,999,059

                  • 0.00

                  • 9.71

                  • Vanguard Explorer Fund

                  •  

                    600,440

                  • 0.00

                  • 2.92

                  • Fidelity® Advisor Small Cap Opps Fund

                  •  

                    349,547

                  • -22.35

                  • 1.70

                  • Fidelity Advisor® Biotechnology Fund

                  •  

                    291,271

                  • 0.00

                  • 1.41

                  • Hartford Small Company HLS Fund

                  •  

                    261,982

                  • -1.08

                  • 1.27

                  • Wells Fargo Advantage Emerging Gr Fund

                  •  

                    221,734

                  • -0.13

                  • 1.08

                  • iShares Russell 2000 (AU)

                  •  

                    218,255

                  • 3.59

                  • 0.93

                  • Vanguard Total Stock Mkt Idx

                  •  

                    206,935

                  • 0.00

                  • 1.00

                  • Franklin Biotechnology Discovery

                  •  

                    191,052

                  • 22.51

                  • 0.94

                  • Hartford Small Company Fund

                  •  

                    168,757

                  • -0.61

                  • 0.82

                  • Institution Name

                  • Shares Held

                  • % Change

                  • % Outstanding

                  • Fidelity Management and Research Company

                  •  

                    3,027,338

                  • +1.04%

                  • 14.70

                  • New Enterprise Associates, LLC

                  •  

                    2,884,221

                  • 0.00%

                  • 14.24

                  • Wellington Management Company, LLP

                  •  

                    2,524,998

                  • -0.43%

                  • 12.26

                  • NEA Management Company, LLC

                  •  

                    2,384,221

                  • -17.34%

                  • 11.58

                  • SOFINNOVA VENTURE PARTNERS VII LP

                  •  

                    2,357,221

                  • 0.00%

                  • 11.64

                  • Sofinnova Management VII, L.L.C.

                  •  

                    1,939,474

                  • -17.72%

                  • 9.57

                  • Bay City Capital LLC

                  •  

                    1,915,656

                  • 0.00%

                  • 9.46

                  Company Profile

                  Sector

                  Healthcare

                  Industry

                  Biotechnology

                  Type

                  -

                  Style

                  -

                  Hyperion Therapeutics Inc., was incorporated in Delaware on November 1, 2006. The Company completed its initial public offering on July 2012. It is a commercial biopharmaceutical company, engaged in the development and commercializat...moreion of novel therapeutics to treat disorders in the areas of orphan diseases and hepatology. Its products, RAVICTI (glycerol phenylbutyrate) Oral liquid, BUPHENYL and AMMONAPS (sodium phenylbutyrate) Tablets and Powder, are designed to lower ammonia in the blood. The Company has developed RAVICTI to treat urea cycle disorders including 7 of the 8 prevalent UCD subtypes, and is developing glycerol phenylbutyrate, the active pharmaceutical ingredient in RAVICTI, to treat hepatic encephalopathy. RAVICTI is indicated for use as a nitrogen-binding agent for chronic management...more of adult and pediatric patients above 2 years of age with urea cycle disorders who cannot be managed by dietary protein restriction and/or amino acid supplementation alone. It distributes RAVICTI through two specialty pharmacies with a single dedicated call center responsible for interfacing with patients, physicians and payors. BUPHENYL is indicated in all patients with neonatal-onset deficiency (complete enzymatic deficiency, presenting within the first 28 days of life). It is also indicated in patients with late-onset disease (partial enzymatic deficiency, presenting after the first month of life) who have a history of hyperammonemic encephalopathy. The Company faces competition from established pharmaceutical and biotechnology companies, as well as from academic institutions, government agencies and private and public research institutions, among others, which may in the future develop products to treat UCD or HE. The Company is subject to numerous federal, state and local laws relating to such matters as safe working conditions, manufacturing practices, environmental protection, fire hazard control, and disposal of hazardous or potentially hazardous substances.lessless

                  Key People

                  Donald J. Santel

                  CEO/Director/President

                  Dr. James I. Healy

                  Chairman of the Board/Director

                  Mr. Jeffrey S. Farrow

                  CFO/Chief Accounting Officer

                  Lota S. Zoth

                  Director

                  Theodore R. Schroeder

                  Director

                  • Hyperion Therapeutics Inc

                  • 2000 Sierra Point Parkway

                  • Brisbane, CA 94005

                  • USA.Map

                  • Phone: +1 650 745-7802

                  • Fax: +1 650 871-7029

                  • hyperiontx.com

                  Incorporated

                  2006

                  Employees

                  54

                  Send Feedback

                  We appreciate your input!

                  • I'm having trouble signing into my Microsoft account

                  • I’m having problems with the services stripe (Mail, Facebook, etc.)

                  • There is an issue with my weather information

                  • I see an error in the content

                  • Other

                  Please give an overall site rating: